sex determining region YGenealiases: SRXX1 · SRXY1 · TDF · TDY
Q-omics provides the consensus-scored SRY profile across patient tissues and cancer cell-line models. SRY expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SRY is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, SRY RNA expression shows 7,157 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where SRY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRY survival associations across molecular data types. SRY RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRY RNA expression–survival associations across cancer types. High SRY expression shows unfavorable associations in UVM, CHOL, LGG and UCEC, but favorable associations in HNSC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SRY RNA expression.
This table summarizes SRY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SRY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRY shows lower tumor expression in KIRC, LUAD, PRAD, CHOL, KIRP and KICH. The KIRC box plot shows higher SRY RNA expression in normal versus tumor tissue (log2 FC = −0.085, t-test p < 0.001).
This table shows molecular features associated with SRY in patient tissues and cancer cell lines. In patient samples, SRY shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SRY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
